Avidicure
Pre-clinicalAvidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer
Founded
2020
Focus
AntibodiesBiologics
About
Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer
Funding History
1Total raised: $2.8M
Seed$2.8MBioGeneration VenturesSep 15, 2021
Company Info
TypePrivate
Founded2020
LocationLeiden, Netherlands
StagePre-clinical
Contact
SIMILAR COMPANIES
2-BBB Medicines
Pre-clinical · Leiden
Batavia Biosciences
Pre-clinical · Leiden
Bilthoven Biologicals
Pre-clinical · Bilthoven
Agendia
Pre-clinical · Amsterdam
Alloksys Life Sciences
Phase 2 · Wageningen
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile